Professor Richard Price
Contact information
Research groups
Ethiopian Clinic
Vietnam Hospital
Richard Price
Professor of Tropical Medicine
- Wellcome Clinical Fellow, Asia Pacific, Australia
Vivax malaria
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with 15 malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- define the direct and indirect morbidity and mortality of vivax malaria
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria,
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN) and co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
CURRENT PROJECTS:
- Clinical trials of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Ex vivo drug susceptibility of novel antimalarial compounds
Timika, Papua, Indonesia
RSMM Hospital
Sumatra Site for IMPROV Study
Ex vivo Lab
Key publications
-
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price RN. et al, (2014), The Lancet Infectious Diseases, 14, 982 - 991
-
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price RN. et al, (2004), The Lancet, 364, 438 - 447
-
Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia
Tjitra E. et al, (2008), PLoS Medicine, 5, e128 - e128
-
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
Douglas NM. et al, (2017), PLOS Medicine, 14, e1002379 - e1002379
-
The effect of dose on the antimalarial efficacy of artemether–lumefantrine: a systematic review and pooled analysis of individual patient data
(2015), The Lancet Infectious Diseases, 15, 692 - 702
-
The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
(2013), PLoS Medicine, 10, e1001564 - e1001564
Recent publications
-
An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples
Ahouidi A. et al, (2021), Wellcome Open Research, 6, 42 - 42
-
Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting
Ruwanpura VSH. et al, (2021), Asia and the Pacific Policy Studies
-
Diagnostic Practices and Treatment for P. vivax in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study
Nguyen TT. et al, (2020), Pathogens, 10, 26 - 26
-
Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy.
Chotsiri P. et al, (2020), Antimicrobial agents and chemotherapy
-
Multi-locus genotyping reveals established endemicity of a geographically distinct Plasmodium vivax population in Mauritania, West Africa
Ba H. et al, (2020), PLOS Neglected Tropical Diseases, 14, e0008945 - e0008945
-
Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea
Miotto O. et al, (2020), PLOS Pathogens, 16, e1009133 - e1009133